Donna Mayer, Executive Director, Cholangiocarcinoma Foundation
Topic: Using Patients Own Immune System to Knock-out Cancer: Adoptive Cell Therapy Date: Date: Thursday, October 23, 2014 Time: 4:00 5:00 PM (Eastern) Presenters: Steven A. Rosenberg, M.D., Ph.D., National Cancer Institute Eric Tran, Ph.D., National Institutes of Health Surgery Branch, Tumor Immunology Section Melinda Bachini, CCF Patient Advocate and NIH Research Study Participant Bios: Steven A. Rosenberg, M.D., Ph.D. Dr. Rosenberg is Chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and at the George Washington University School of Medicine and Health Sciences in Washington, D.C. He. received his B.A. and M.D. degree at The Johns Hopkins University in Baltimore, Maryland and a Ph.D. in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston Massachusetts, Dr. Rosenberg became the Chief of Surgery at the National Cancer Institute, a position he has held to the present time. Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. His recent studies of cell transfer immunotherapy have resulted in durable complete remissions in
patients with metastatic melanoma. He has also pioneered the
development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes has resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas. Dr. Rosenberg is a member of the American Society of Clinical Oncology and served on its Board of directors. He is also a member of the Institute of Medicine of the National Academy of Sciences, the Society of University Surgeons, the American Surgical Association, the American Association for Cancer Research, and the American Association of Immunologists among others. Dr. Rosenberg is the author of over 950 articles in the scientific literature covering various aspects of cancer research and has authored 8 books. Eric Tran, Ph.D. Dr. Tran received his PhD in biochemistry from the University of Victoria in British Columbia, Canada, and is currently a postdoctoral fellow in the lab of Dr. Steven Rosenberg at the National Institutes of Health. Dr. Trans goal is to develop effective T-cell therapies against common solid cancers. This has led him to investigate the T-cell response against cancer mutations in patients with metastatic gastrointestinal (GI) cancers. His recent work on a patient with cholangiocarcinoma suggests that the adoptive transfer of T cells targeting a mutation uniquely expressed by that patients metastatic cancer appears capable of mediating tumor regression. Dr. Trans current efforts are focused on determining how often mutationreactive T cells can be found patients with metastatic GI cancers and on developing methods to better harness the mutation-specific T-cell response against cancers. Melinda Bachini At 46 years old, I am a wife and a mother of six beautiful children. My story began the end of October 2009 when I began to experience
some extreme heartburn symptoms, tightness around my epigastric
region and indigestion. I thought at the time that I might have gallstones. On December 1st, 2009, I was diagnosed with Intrahepatic Cholangiocarcinoma. Three weeks later I had 2/3rds of my liver resected with good margins. Unfortunately, at my three month checkup, metastasis was confirmed in my lungs. I went to the Mayo Clinic in Rochester for a second opinion on my options, but they recommended the same treatment of Gemzar and Cisplatinin. They had no clinical trials available for me at that time. I did the regimen of Gem/Cis for about 5 months with stable disease. Due to the toxicity of the Cisplatin they put me on Gemzar alone which resulted in growth in tumors. I was then switched to Avastin, which held the tumors at bay for a few months. I began having toxicity to the Avastin as well. After many attempts at trying chemotherapy, I found myself not wanting to spend the rest of the life I had left using a chemo that would not cure me but had already caused so much damage. Chemo was toxic and it was not holding against this growing cancer within me. I found the NIH clinical trial shortly after this decision. It involved the initial chemo to deplete my immune system but after that it was my body fighting the cancer. In March of 2012, two years and four months after diagnosis, I entered into this trial at the National Cancer Institute in Bethesda, Maryland. I have had huge success with this treatment and I am hoping and praying that it will also benefit many others! Quick Cholangiocarcinoma Facts: Of the 580,000 Americans diagnosed with cancer every year, 2,500 of those cases are Cholangiocarcinoma. There is only a 30 per cent chance of a five-year survival rate if the cancer is found early stage, and the cause is still unknown. This disease can hit at any age, but typically occurs in patients over 65 years old. Bile seeps back into the blood causing the patients skin and whites of their eyes to become
yellow. Other symptoms include abdominal pain, high temperatures
and weight loss. What: Scientists and doctors have taken an important step forward in a new cancer treatment. The therapy can apply to a wide array of cancers especially patients who have been diagnosed with melanomas in the lungs, bladder and gastrointestinal tract. A study recently published by the National Cancer Institute, under the National Institutes of Health, doctors sequenced the genome of a 43-year-old woman named Melinda Bachini, who had been struggling a cancer that wasnt responding to chemotherapy. According to the Times Dr. Steven A. Rosenberg and his colleagues preformed adopted cell therapy, on the patient which involves identified cells from her immune system that attacked a specific mutation in the malignant cells. Then they grew those immune cells in the laboratory and infused billions of them back into her bloodstream. Through this process the tumors started to melt away. Rosenberg told NBC News Its the first time we have been able to actually target a specific mutation in the immune system, Why: This womans cancer is not cured. While her tumors are shrinking, they are not gone. But this report shows an approach that can be applied to most common tumors, which cause more than 80% of the 580,000 cancer deaths in the United States every year. This is a great breakthrough in science. Rosenberg will discuss the techniques used in hopes to continue to find the cure. Because of this study scientist may one day use modifies E.coli to develop custom drugs, antibiotics, and vaccines that were never possible before.